This startup is developing rapid biosensors for pathogen diagnostics, with an initial focus on creating a fast blood test for sepsis. Their technology aims to significantly reduce the time to diagnosis, improving patient outcomes in critical care situations.
Funding
Funding not disclosed
Founders
Product
Problem
Sepsis diagnosis relies on blood cultures that can take 24-72 hours, delaying appropriate treatment and increasing mortality rates. Current diagnostic methods often lack the speed and sensitivity needed for early detection in critical care settings.
Solution
ReachSci is developing rapid biosensors for point-of-care pathogen diagnostics, enabling faster and more accurate detection of sepsis-causing agents directly from a blood sample. Their technology utilizes advanced microfluidics and nanomaterials to capture and identify pathogens within minutes, significantly reducing the time to diagnosis compared to traditional blood cultures. By providing clinicians with actionable information sooner, ReachSci aims to improve patient outcomes, reduce unnecessary antibiotic use, and lower healthcare costs associated with prolonged hospital stays. The platform is designed for ease of use in emergency departments, intensive care units, and other critical care environments.
Target Audience
The primary target audience includes hospitals, emergency departments, intensive care units, and clinical laboratories seeking faster and more accurate sepsis diagnostics.
Features
- Multiplexed detection of a broad panel of sepsis-causing bacteria and fungi
- Integrated microfluidic cartridge for automated sample preparation and analysis
- Nanomaterial-enhanced biosensors for increased sensitivity and specificity
- Point-of-care device with a user-friendly interface for rapid results
- Wireless connectivity for seamless data transfer to electronic health records